Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activity

BMC Health Services Research

Volumn 13, Issue 1, 2013, Pages

  Raimundo, Karina ^a,b   Tian, Haijun ^a   Zhou, Huanxue ^c   Zhang, Xin ^d   Kahler, Kristijan H ^a   Agashivala, Neetu ^a   Kim, Edward ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF UTAH   (United States)

^c KMK Consulting Inc   (United States)

^d Novartis Beijing Novartis Pharma Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL PRACTICE; ECONOMICS; FEMALE; HEALTH CARE PLANNING; HUMAN; INSURANCE; LONGITUDINAL STUDY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; UNITED STATES; UTILIZATION REVIEW;

ADOLESCENT; ADULT; AGED; FEMALE; HEALTH RESOURCES; HUMANS; INSURANCE CLAIM REVIEW; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84875850566     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-13-131     Document Type: Article

References (19)

1. Studies on the natural history of multiple sclerosis. Correlates of clinical change in an early bout. Kurtzke JF, Beebe GW, Nagler B, Auth TL, Kurland LT, Nefzger MD, Acta Neurol Scandinav 1973 49 379 395
2. Managing symptoms of multiple sclerosis. Shapiro RT, Neurol Clin 2005 23 177 187 10.1016/j.ncl.2004.09.001 15661093
3. National Multiple Sclerosis Society (NMSS), What We Know about MS [ http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/ symptoms/index.aspx ]
4. Surrogate endpoints for EDSS worsening in multiple sclerosis. Sormani MP, Bonzano L, Roccatagliate L, Mancardi GL, Uccelli A, Bruzzi P, Neurology 2010 75 302 309 10.1212/WNL.0b013e3181ea15aa 20574036
5. Cost of managing an episode of relapse in multiple sclerosis in the United States. O'Brien JA, Ward AJ, Patrick AR, Caro J, BMC Health Serv Res 2003 3 17 10.1186/1472-6963-3-17 12952552
6. Multiple sclerosis. Is prevalence rising and if so why? Benito-León J, Neuroepidemiology 2011 37 236 237 10.1159/000334606 22133765
7. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Kobelt G, Berg J, Atherly D, Hadjimichael O, Neurology 2006 66 1696 1702 10.1212/01.wnl.0000218309.01322.5c 16769943
8. Natural history of multiple sclerosis. Weinshenker BG, Ann Neurol 1994 36 Suppl 6 S11 8017890
9. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H, Ann Neurol 2000 47 707 717 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q 10852536
10. Thomson Reuters, Marketscan® Medicaid Multi-State Database [ http://marketscan.thomsonreuters.com/marketscanportal/ ] 23580074
11. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. Ollendorf DA, Jilinskaia E, Oleen-Burkey M, J Managed Care Pharm 2002 8 469 476
12. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV, J Med Econ 2010 13 618 625 10.3111/13696998.2010.523670 20883151
13. Estimating medication persistency using administrative claims data. Sikka R, Xia F, Aubert RE, Am J Managed Care 2005 11 449 457
14. Guidelines for selecting among different types of bootstraps. Baser O, Crown WH, Pollicino C, Curr Med Res Opin 2006 2 799 808
15. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Schumacher GA, Beebe G, Kibler RF, Ann NY Acad Sci 1965 122 552 568 14313512
16. Economic assessment of the relationship between disease exacerbations and the cost of multiple sclerosis. Grudzinski AN, Hakim Z, Cos ER, Labiner DM, Bootman JL, J Manag Care Pharm 2000 6 19 24
17. Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. Río J, Tintoré J, Sastre-Garriga C, Eur J Neurol 2012 19 899 904 10.1111/j.1468-1331.2011.03648.x 22289050
18. Reasons patients give to use or not to use immunomodulating agents for multiple sclerosis. Visser LH, van der Zande A, Eur J Neurol 2011 18 1343 1349 10.1111/j.1468-1331.2011.03411.x 21496180
19. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Prosperini L, Giannì C, Leonardi L, Mult Scler 2012 18 64 71 10.1177/1352458511417481 21828195